08:40 AM EDT, 09/05/2024 (MT Newswires) -- Cigna Group ( CI ) subsidiary Evernorth Health Services said Thursday that it plans to make available a biosimilar version of Stelara without cost to eligible patients of its specialty pharmacy Accredo beginning early 2025.

The drug will be produced for Evernorth's affiliated distributor, Quallent Pharmaceuticals.

The company said the addition of the drug could save patients $4,000 a year.

Stelara and its biosimilars are used for the treatment of various inflammatory conditions.

Price: 364.51, Change: -2.13, Percent Change: -0.58